ExpreS2ion Biotech Holding AB (publ) (EXPRS2) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to today's presentation where we have the pleasure to present expression biotechnologies. To help us through today's presentation and talk a little bit about results and answer questions in the end, we are joined by CEO Ben Franson and CFO Keith Alexander. Today's topic, of course, your Q2 report out fresh from the press, but I guess also the bigger, broader picture of what has been a lot, I think a very busy news flow over the summer by you and in the early spring. As always, ask questions down in the box down below. We already got a lot in. See if it's already answered. I would also say we have a firm deadline at 11 o'clock, unfortunately. But you are very welcome to send in the questions if you don't get to the IR webmail by you. And I know, Ben, I have seen your program. You also have a lot of presentations other places. So maybe the questions can be asked there. But for now, I'll hand the call over to you, Ben. Thank you very much, Michael. My name is Ben Funsen. I'm the CEO of Expression Biotechnologies, and I'm joined here by Keith Alexander, our CFO. And we'll be going through Expression where we are today on the back of the Q2 report that we just released today. we have some exciting uh information here coming up we'll be going through our strategy and pipeline subsequently the financial results and allowing some time for q a as michael also a little too and first going through strategy and pipeline i think the important keyword here is momentum we have been following up on announcement we've been making earlier uh making progress, especially on our first cancer vaccine assets in clinical stage one. And this we're going to talk through. Just in the beginning here, let's just all be clear on expression strategy. It's a laser focused, we have first and...